San Diego, CA – August 14, 2006 – Ambrx Inc. announced today today that it has been issued U.S. Patent No. 7,083,970 entitled "Methods and Compositions for the Production of Orthogonal tRNA – Aminoacyl tRNA Synthetase Pairs." The patent covers Am… Read More

San Diego, CA – July 24, 2006 – Ambrx, Inc., announced today it has secured commitments for an additional $3 million in Series C financing. This further investment, which was provided by Scottish Widows Investment Partnership, brings the total secured in the Company's Series C financing to $55 million. Net … Read More

San Diego, CA – July 19, 2006 – Ambrx Inc. announced today the appointment of Kevin L. Eastwood as vice president of corporate development. Eastwood, who has over 17 years of business development, sales and marketing experience within the biotech and pharmaceutical industry, will focus on t… Read More

San Diego, CA – July 05, 2006 – Ambrx Inc. announced today it has secured commitments for $52 million in Series C financing from a broad, international syndicate of new and existing investors. Net proceeds will be used to further expand Ambrx’s novel protein modification platform, support the development of its prod… Read More

San Diego, CA – May 23, 2006 – Ambrx Inc. announced today that it has been issued U.S. Patent No. 7,045,337 entitled "In vivo incorporation of unnatural amino acids." The patent covers Ambrx’s core ReCODE™ technology, which serves as the basis for the devel… Read More

San Diego, CA – May 23, 2006 – Ambrx Inc. announced today that it has been issued U.S. Patent No. 7,045,337 entitled "In vivo incorporation of unnatural amino acids." Aker, who has held senior positions with biopharmaceutical and medical device companies, wil… Read More

La Jolla, California – January 10, 2006 – Ambrx, Inc. today announced that Martin A. Mattingly, the Company’s president and chief executive officer, will present an overview of Ambrx’s research and development activities at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, at 9:… Read More